Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2010

01-12-2010 | Letter to the Editor

Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer

Authors: Shih-Chung Wu, Fong-Fu Chou, Kun-Ming Rau

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Excerpt

To the Editor, …
Literature
1.
Kim HS, Park YH, Park MJ et al (2009) Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 118:89–97CrossRefPubMed
2.
Molina R, Zanon G, Filella X et al (1995) Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41–48CrossRefPubMed
3.
Hou MF, Chen YL, Tseng TF et al (1999) Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 15:520–528PubMed
4.
Kufe D, Inghirami G, Abe M et al (1984) Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223–232CrossRefPubMed
5.
Klee GG, Schreiber WE (2004) MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA15-3, CA27.29, BR). Arch Pathol Lab Med 128:1131–1135PubMed
6.
Reddish MA, Helbrecht N, Almeida AF et al (1992) Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC1 gene. J Tumor Marker Oncol 7:19–27
7.
Gourevitch MM, Von Mensdorff-Pouilly S, Litvinov SV et al (1995) Polymorphic epithelial mucin (MUC-1)-containing circulating immunocomplexes in carcinoma patients. Br J Cancer 72:934–938PubMed
1.
Kim HS, Park YH, Park MJ et al (2009) Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 118:89–97CrossRefPubMed
2.
Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345–351CrossRefPubMed
3.
Hashimoto K, Yonemori K, Katsumata N, et al (2010) Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. Ann Oncol [Epub ahead of print]
4.
Baskić D, Ristić P, Matić S et al (2007) Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers 12:657–667CrossRefPubMed
5.
Tampellini M, Berruti A, Bitossi R et al (2006) Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat 98:241–248CrossRefPubMed
6.
Duffy MJ (2001) Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34:347–352CrossRefPubMed
7.
8.
Jonckheere N, Van Seuningen I (2010) The membrane-bound mucins: From cell signaling to transcriptional regulation and expression in epithelial cancers. Biochimie 92:1–11CrossRefPubMed
9.
Yonezawa S, Goto M, Yamada N et al (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8:3329–3341CrossRefPubMed
10.
Bafna S, Kaur S, Batra SK (2010) Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29:2893–2904CrossRefPubMed
11.
Vogelzang NJ, Lange PH, Goldman A et al (1982) Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42:4855–4861PubMed
12.
Horwich A, Peckham MJ (1986) Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Res 70:1329–1331
13.
Sella A, Sternberg CN, Skoneczna I et al (2008) Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int 102:1607–1609CrossRefPubMed
14.
Nelius T, Filleur S (2009) PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 69:1802–1807CrossRefPubMed
15.
De Wit R, Collette L, Sylvester R (1998) Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78:1350–1355PubMed
16.
An X, Ding PR, Xiang XJ et al (2010) Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers 15:243–248CrossRefPubMed
17.
Ailawadhi S, Sunga A, Raiput A et al (2005) Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 70:49–53CrossRef
Metadata
Title
Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Authors
Shih-Chung Wu
Fong-Fu Chou
Kun-Ming Rau
Publication date
01-12-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1117-3

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue

Brief Report

Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report

Epidemiology

A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer

Clinical trial

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features

Invited Commentary

The androgen receptor in breast cancer: learning from the past

Epidemiology

Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients

Preclinical study

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits